PER® Miami Breast Cancer Conference

Reshma Jagsi, MD, Dphil, discusses factors that could influence the omission of radiation therapy following breast-conserving surgery in early-stage breast cancer.

Patrick I. Borgen, MD, discusses the need for improved risk stratification in early-stage breast cancer.

Imlunestrant generated PFS benefit with or without abemaciclib for select patients with ER-positive, HER2-negative advanced breast cancer.

Treatment with sacituzumab govitecan was effective and tolerable in real-world patients with mTNBC who received the agent in later-line settings.

The real-world use of ribociclib plus ET is in line with recommended dosing and the regimen’s use has been increasing in mBC, according to EHR and KRD data.

A post hoc analysis of the NATALEE trial suggests that ribociclib dose reduction preserves iDFS in hormone receptor+/HER2-negative early breast cancer.

Sacituzumab govitecan was active with low rates of neutropenia—especially in patients receiving G-CSF—in real-world metastatic TNBC.

Reshma L. Mahtani, DO, discusses unique challenges women may face when transitioning between different career roles within oncology.

Reshma Mahtani, DO, spotlights the challenges women in oncology may face throughout their careers and gives some advice to those just starting out.

Hope S. Rugo, MD, draws on her own journey as a woman in oncology to provide insights on navigating career transitions and building support networks.

Stephanie L. Graff, MD, shares her journey to becoming an oncologist, advice for work-life balance, and ways to confront gender bias in medicine.

Jennifer K. Plichta, MD, MS, discusses key areas of interest regarding the role and optimization of genetic testing in breast cancer.

Shelley Hwang, MD, MPH, discusses the potential use of multicancer early detection tests in breast cancer screening.

Rachel Jimenez, MD, discusses unmet needs in radiation treatment for patients with breast cancer.

Stephanie L. Graff, MD, discusses the trajectory of her career growth in breast oncology and explains how different factors can play a role in an oncologist’s career path.

Hope S. Rugo, MD, discusses challenges that women face in the workplace in oncology care.

Heather McArthur, MD, MPH, discusses the prognostic benefits of circulating tumor DNA and limitations that prevent these results from being predictive.

Debu Tripathy, MD, discusses current considerations for the management of early-stage HER2-positive breast cancer.

Debu Tripathy, MD, provides insights on the management of HER2-positive breast cancer, including the evolving role of trastuzumab in this population.

Hope Rugo, MD, discusses the evolution of antibody-drug conjugates in hormone receptor–positive, HER2-positive, and HER2-low breast cancer.

Erica Stringer-Reasor, MD, highlights the evolution of therapies for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Laura A. Huppert, MD, discusses data informing the sequence of immunotherapy and chemotherapy regimens in early-stage triple-negative breast cancer.

Terry P. Mamounas, MD, MPH, FACS, discusses treatment options after neoadjuvant chemotherapy and how neoadjuvant chemotherapy influences axillary surgery.

PRMT5 inhibitors with antiestrogens represents a therapeutic strategy that may overcome resistance to CDK4/6 inhibitors in ER+/RB-deficient breast cancer.

Hope S. Rugo, MD, FASCO, shares progress made with ADCs and the interest in moving these agents up in the HR-positive/HER2-negative breast cancer paradigm.

Racial and ethnic disparities for mortality are present in breast cancer, especially as it relates to radiation therapy toxicity and cardiac dose.

Jennifer K. Litton, MD, discusses challenges determining the optimal sequencing of PARP inhibitors in early-stage triple-negative breast cancer.

Kevin Kalinsky, MD, MS, discusses questions regarding the utility and implementation of genomic testing approaches in hormone receptor–positive breast cancer.